Skip to main content

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs have been used or studied for several urologic indications: stress urinary incontinence (SUI), the most-studied, with duloxetine approved for SUI in Europe but not the US; post-prostatectomy incontinence (PPUI); mixed urinary incontinence; overactive bladder; chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS); chronic pelvic pain in women; and premature ejaculation. Duloxetine is the dominant SNRI in urology; venlafaxine and milnacipran / levomilnacipran have limited direct urologic evidence and distinct safety constraints. SNRIs also produce clinically important urologic adverse effects, including urinary hesitation / retention (FDA warning) and sexual dysfunction, that urologists must actively recognize.[1][2][3]

For class-comparison context see Tricyclic antidepressants and Gabapentinoids. For the conditions and procedures these agents orbit, see Female SUI, Urethral Bulking Agents, Chronic Pelvic Pain, and IC/PBS.

Mechanism — Modulation of Onuf's Nucleus and the Continence Reflex​

Motor neurons in Onuf's nucleus (sacral spinal cord) control the external urethral sphincter (rhabdosphincter) and carry uniquely dense serotonergic and noradrenergic terminals. Duloxetine raises extracellular 5-HT and NE in the sacral spinal cord and produces three effects relevant to LUT function:[4][5][6][7]

  1. Facilitation of rhabdosphincter contraction during the storage phase. 5-HT and NE amplify the excitatory effect of glutamate on sphincter motor neurons.[4][5] Glutamate is the on/off switch, so duloxetine enhances sphincter activity during storage with preserved voiding relaxation in experimental models.[4][5]
  2. Suppression of bladder overactivity under irritated conditions. In animal models duloxetine produces dose-dependent increases in bladder capacity (up to 5×) and periurethral sphincter EMG activity (up to 8×), with minimal effect under normal conditions. Capacity effects are mediated through 5-HT receptors; sphincter facilitation involves 5-HT2 and α1-adrenergic mechanisms.[6]
  3. Enhanced active continence reflex. In normal rats, duloxetine increased sneeze-evoked urethral pressure, leak point pressure, and baseline urethral pressure; it did not increase urethral responses after cerebral infarction. Human studies summarized by Schuessler reported higher Valsalva leak point pressure and rhabdosphincter activity in duloxetine responders with SUI, but no relevant resting-tone effect in healthy women.[4][7]

This is mechanistically distinct from TCAs: SNRIs lack antimuscarinic, antihistaminic, and direct smooth-muscle-relaxant activity.[2][4]

SUI in Women — the principal urologic application​

Yentreve is licensed in Europe for moderate-to-severe SUI in adult women; duloxetine has no US SUI approval. NICE advises against first-line or routine second-line use, but allows a selected second-line trial when a woman prefers medication to surgery or is unsuitable for surgery. EAU likewise gives a weak recommendation for selected women who remain symptomatic after conservative treatment and wish to avoid an invasive intervention. Counsel about adverse effects and discontinuation. EAU rates starting and stopping by dose titration as a Strong recommendation because adverse events are frequent, and extends the same weak, selected-patient offer (where licensed) to stress-predominant mixed incontinence. For women with mild SUI (fewer than 14 incontinence episodes per week in the trials), the Yentreve label reports no demonstrated benefit versus placebo and says benefit beyond conservative behavioral measures may be absent.[1][45][46][47]

Cochrane review (10 RCTs, n = 3,944)[10]​

  • Subjective cure favored duloxetine 80 mg/day only marginally (pooled RR for "not cured" 0.97, 95% CI 0.93–1.00; p = 0.04); about three more women cured per 100 treated[10]
  • about 50% reduction in incontinence episode frequency in individual studies[10]
  • QoL improved (pooled WMD 5.26, 95% CI 3.84–6.68); objective pad-test/24-hour pad-weight cure was not established.[10] About one in eight duloxetine-treated participants stopped because of adverse effects in this review. A later clinical-study-report meta-analysis of four placebo-controlled trials (1,913 women) estimated an NNT of 8 for feeling much or very much better in a sensitivity analysis and an NNH of 7 for adverse-event discontinuation.[55]

ACP’s older guidance recommended against systemic pharmacologic treatment for female SUI; this differs from the selected-use option in NICE/EAU.[11][46][47]

Licensed SUI dosing (Europe)​

40 mg twice daily is the Yentreve dose.[45] An initial 20 mg twice daily for two weeks can improve tolerability before escalation.[45] Reassess at 2–4 weeks and regularly thereafter; placebo-controlled efficacy beyond three months has not been evaluated. Taper over at least 2 weeks on withdrawal; withdrawal symptoms are usually self-limiting but can last months. A 120 mg/day regimen tested for OAB is not the 40 mg twice-daily SUI label dose.[25][45]

Duloxetine + pelvic floor muscle training (PFMT)​

Combination therapy may offer greater symptom improvement than either treatment alone.[12][13][14]

TrialComparisonResult
Ghoniem 2005 (RCT, n = 201; 80 mg/day, 12 wk)Duloxetine + PFMT vs each alone vs no treatment[14]IEF: duloxetine with or without PFMT superior to no treatment or PFMT alone; pad use and I-QoL favored the combination over either single treatment
DULOXING 2021 (RCT, n = 158)Duloxetine + innovative PFMT vs duloxetine alone[12]IEF reduction 66.7% vs 50.0%; better ICIQ-SF, PGI-I 70.8% vs 65.6%, I-QoL +19.3% vs +6.6% (all p < 0.05)
Svihra 2021QALY analysis[13]Model projected QALYs over estimated remaining life expectancy (17.90 vs 15.03), using short-term utility scores

Sexual function​

Although SNRIs are associated with sexual dysfunction, in an uncontrolled two-month before–after study of 40 sexually active women with SUI receiving duloxetine 40 mg twice daily, mean FSFI increased from 19.9 to 25.7 (p < 0.001).[15]

Post-Prostatectomy Incontinence​

There is no approved pharmacotherapy for PPUI. Duloxetine is the most-studied agent, used off-label.

Selected RCTs and series​

StudyDesignKey finding
Cornu 2011 (RCT, n = 31)[16]Duloxetine 80 mg/day vs placebo × 3 mo in post-RP SUIIEF reduction −52.2% vs +19.0% (MD 71.2%, p < 0.0001); improvement in selected symptom/QoL measures
Filocamo 2007 (RCT, n = 112 randomized; 102 completed)[17]Duloxetine + rehab vs rehab alone × 16 wk post-catheterAmong completers, at 16 wk, 39 vs 27 patients dry (p = 0.007). At 20 wk, four weeks after planned discontinuation, 23 versus 38 were dry (p = 0.008); by 24 wk, 31 versus 41 were dry (p = 0.08).
Sanchez-Salas 2024 (RCT, n = 240, 4-arm)[18]PFMT-biofeedback ± duloxetine vs controlAt 6 mo, continence defined as ≤1 security pad: control 96% vs PFMT-biofeedback 90%, duloxetine 73% (p = 0.008), combined 69% (p = 0.003); QoL rated uncomfortable or worse in 44% (PFMT), 45% (duloxetine) and 34% (combined) vs 17% of controls
Kang 2023 (retrospective, n = 197)[19]PFME + duloxetine 30 mg vs PFME aloneCombination better at 2 wk (p = 0.019); no difference at 3, 6, 9, or 12 mo
Schlenker 2006 (open-label, n = 20: 15 after radical prostatectomy and 5 after cystectomy with orthotopic neobladder)[20]Duloxetine 80 mg/day for a mean 9.4 wkIn the mixed cohort, pad use fell from 8.0 to 4.2/day (p < 0.001); six of 20 discontinued because of severe adverse effects
Collado Serra 2011 (open-label, n = 68, established PPUI)[21]Duloxetine in chronic (> 1 yr) PPUIICIQ-SF 13 → 9 at the 3-month visit (p < 0.001)

Practical interpretation​

Duloxetine may reduce leakage while taken by selected men, but sustained recovery is uncertain and the 240-person trial did not support routine use to accelerate recovery. EAU offers it weakly as an off-label option, with explicit adverse-effect counseling. A trial needs reassessment and a withdrawal plan; it must not delay PFMT or appropriate surgical referral.[48][22]

Mixed Urinary Incontinence​

The dual-mechanism rationale (sphincter facilitation for stress plus indirect modulation of bladder overactivity for urge) is theoretically attractive. Two recent retrospective studies of duloxetine plus tolterodine for urge-predominant mixed UI:

StudyNotes
Sobay 2025 (n = 106)[23]OABSS 11.08 → 6.95; ICIQ-SF 15.69 → 8.84; pads 3.58 → 0.73/day; capacity 315 → 436 mL (all p < 0.001)
Polat 2026 (n = 115)[24]Significant improvement in OABSS, ICIQ-SF, pad weights, frequency, nocturia, urgency, and IEF at weeks 4 and 12

Both studies were retrospective and uncontrolled, and both excluded patients with postvoid residual >150 mL.[23][24] Tolterodine is contraindicated in urinary retention and requires caution with clinically significant bladder outflow obstruction; assess emptying before considering the combination.[54] Yentreve labeling reports 71% higher parent-tolterodine exposure with duloxetine 40 mg twice daily, with unchanged active-metabolite exposure and no recommended dose adjustment.[45] Controlled trials are needed to establish added benefit and sequence.[23][24][45][54]

Overactive Bladder​

Steers 2007 RCT[25]​

In 306 women with OAB symptoms, no SUI, a daytime voiding interval of at most 2 hours, and detrusor overactivity or urgency-limited capacity <400 mL, duloxetine was given at 80 mg/day for 4 weeks then 120 mg/day for 8 weeks versus placebo:[25]

  • Duloxetine reduced voiding and incontinence episodes per 24 hours, increased the mean daytime voiding interval, and improved I-QoL versus placebo at both sequential doses
  • Urodynamics: no significant change in maximum cystometric capacity or volume threshold for DO
  • AEs: nausea (31%), dry mouth (16%), dizziness (14%), constipation (14%), insomnia (13%), fatigue (11%); mean PVR rose by < 5 mL and no patient reported hesitancy or retention[25]

Multiple sclerosis OAB pilot (Di Rezze 2012)[26]​

Crossover trial in MS patients with OAB; significant improvement in OAB-Q with duloxetine versus both baseline and placebo.

Mechanistic preclinical data​

Duloxetine reverses detrusor overactivity and depression-like signs in a corticosterone-treated rat model via central pathways, distinct from solifenacin and mirabegron, which act peripherally. Effects persist 72 h after discontinuation, suggesting neuroplastic changes.[27] For women with OAB who fail conservative management, the EAU guideline strongly recommends offering anticholinergics or beta-3 agonists; it weakly recommends duloxetine where licensed for selected women with stress urinary incontinence or stress-predominant mixed incontinence who remain symptomatic despite other conservative management and wish to avoid invasive treatment.[47] Convergent mouse data show SNRIs improve micturition control across multiple models.[9]

CP/CPPS​

Duloxetine has limited direct study evidence in CP/CPPS. The 2025 AUA male chronic pelvic pain guideline lists TCAs, SSRIs, and gabapentinoids for neuropathic pain ; it does not specifically list SNRIs.[56] For the distinct IC/BPS phenotype, amitriptyline is an AUA oral option.[8]

StudyResult
Giannantoni 2014 (RCT, n = 38)[28]Duloxetine 60 mg + tamsulosin + saw palmetto vs tamsulosin + saw palmetto × 16 wk → significant improvement in NIH-CPSI pain, QoL, and total scores (p < 0.01); 20% of the duloxetine group stopped for adverse effects
Zhang 2017 (150 enrolled, 126 completed; open randomized three-arm study titled observational)[29]Doxazosin + duloxetine vs doxazosin + sertraline vs doxazosin × 6 mo → response among completers (at least a 6-point and 25% NIH-CPSI reduction) 88.6% vs 63.4% vs 56.1%; NIH-CPSI reduction 12.64 vs 7.41 vs 6.12 (p < 0.05)
Cochrane 2019[30]Antidepressant symptom evidence was low to very low certainty; pooled adverse events in three studies (94 participants) did not establish an increased risk (RR 1.65, 95% CI 0.54–5.04; low-certainty evidence)

Duloxetine fits the multimodal UPOINT model (the "P" psychosocial domain or as a pain-modulating add-on), particularly when neuropathic features, anxiety, or depression are present.[31] EAU 2026 cites duloxetine 60 mg/day for diabetic neuropathy and fibromyalgia, notes that side effects are common, and does not recommend it for primary bladder pain syndrome because a trial found no significant symptom improvement.[50]

Chronic pelvic pain in women​

ACOG’s 2020 Practice Bulletin recommends SNRIs for neuropathic CPP (Level B), extrapolating mainly from other neuropathic pain conditions; direct female CPP efficacy remains uncertain.[32] The 2024 SOGC guideline says duloxetine and venlafaxine may be considered for chronic pain management in females with CPP.[52] A 2025 double-blind trial randomized 69 women with CPP to duloxetine or amitriptyline for eight weeks; total NIH-CPSI response (a reduction of at least six points) was similar. Duloxetine had lower pain-domain scores and fewer adverse effects and related withdrawals, while amitriptyline had better urinary-domain scores. The active-comparator design and eight-week follow-up leave absolute efficacy and durability uncertain.[53]

The 2023 Cochrane network meta-analysis (176 studies; 28,664 participants) found the clearest chronic-pain evidence for duloxetine 60 mg/day, mainly in fibromyalgia, neuropathic and musculoskeletal pain. Effects were small to moderate; higher doses generally did not add benefit. The average trial lasted about ten weeks, and long-term efficacy/safety remained uncertain.[49]

Premature Ejaculation​

SSRIs delay ejaculation pharmacologically; SNRI efficacy in PE is inconsistent. Dapoxetine, a short-acting SSRI, is the only serotonergic agent specifically approved (in Europe, not the US) for on-demand PE.[33][34][37]

Cochrane SSRI evidence (31 RCTs, n = 8,254)[35]​

  • IELT increased by 3.09 minutes versus placebo (95% CI 1.94–4.25)[35]
  • Perception of improvement: 2× more likely (NNT 5)
  • Satisfaction: RR 1.63; perceived control: RR 2.29[35]
  • In this Cochrane placebo subgroup, paroxetine increased IELT by a mean 6.51 min (95% CI 0.33–12.68; three studies, 107 men).[35] EAU 2026 describes paroxetine as producing the most substantial delay among common SSRIs on additional evidence.[35][57]
  • Discontinuation due to AEs: NNH 33

Venlafaxine for PE — failed RCT​

Safarinejad 2008 (RCT, n = 222): venlafaxine 75 mg XR versus placebo × 12 weeks; no significant difference in IELT (1.7× versus 1.6×), intercourse satisfaction, or weekly coitus episodes. AEs more common with venlafaxine. Conclusion: "venlafaxine is not better than placebo in treatment of PE."[36]

Duloxetine for PE​

The AUA/SMSNA 2020 Disorders of Ejaculation guideline (published 2022) reviews duloxetine 40 mg/day and venlafaxine 75 mg/day in the discussion of Statement 14.[37] It reports a modest IELT benefit for duloxetine and no significant benefit for venlafaxine compared with placebo. The guideline lists duloxetine and venlafaxine among alternative PE therapies with limited evidence; Statement 14 says evidence is insufficient to support alternative PE therapies .[37] In a subsequent randomized crossover trial, 68 of 100 randomized men completed treatment; 91.2% had acquired PE, and median IELT after a two-month duloxetine regimen was 180 seconds versus 60 seconds after placebo.[58] IELT returned to baseline after stopping.[58]

Dapoxetine​

Meta-analysis of 7 RCTs (n = 8,039): both 30 mg and 60 mg significantly improved IELT and PGIC versus placebo; 60 mg more effective but more AEs.[38] A network analysis ranked dapoxetine 30 mg favorably.[39] Not available in the US.[38][39]

Clinical interpretation​

Among SNRIs, duloxetine has limited evidence; venlafaxine did not outperform placebo in either a two-week crossover pilot (21 of 31 men analyzed) or a 12-week parallel trial (222 men).[59][36][40] AUA/SMSNA 2020 recommends daily SSRIs, on-demand clomipramine or dapoxetine where available, and topical penile anesthetics as first-line PE pharmacotherapy .[37] SNRIs are not included in that first-line list.[37]

Individual SNRI Profiles​

AgentUrologic roleNotable urologic AEs
DuloxetineFemale SUI (EU-labeled); male SUI off-label; other pelvic uses have limited or uncertain evidenceUrinary hesitation / retention (FDA warning); sexual dysfunction; nausea (23% across pooled placebo-controlled trials for approved adult indications, versus 8% with placebo)[1][2]
VenlafaxineNegative PE RCT; no established urologic indicationSexual dysfunction (ejaculatory delay, decreased libido, ED); urinary hesitation[36][41]
DesvenlafaxineNo established urologic therapeutic roleSexual dysfunction; urinary hesitation and retention; systolic orthostatic hypotension (supine-to-standing decrease ≥30 mm Hg) in adults aged 65 years or older (7/87 vs 1/40 on placebo in short-term studies)[60]
MilnacipranFibromyalgia (FDA-approved); pharmacovigilance data only in urologyDysuria, urinary retention, testicular pain, ejaculation disorders — SAVELLA label notes higher GU AE susceptibility in men generally and cautions particularly in men with prostatic hypertrophy or other obstructive urinary disorders[42][43]
LevomilnacipranNo established urologic therapeutic roleShort-term fixed-dose MDD trials reported urinary hesitation in 4% (40 mg/day; n = 366), 5% (80 mg/day; n = 367), and 6% (120 mg/day; n = 180), versus 0% on placebo (n = 362). Monitor BP and sexual adverse effects; use caution in patients prone to obstructive urinary disorders.[44][51]

Urologic Adverse Effects​

Urinary hesitation and retention​

The duloxetine label warns that new hesitancy may be drug-related; postmarketing retention has sometimes required catheterization or hospitalization.[2]

A systematic review of RCTs found antidepressants overall, not SNRIs alone, were associated with more voiding disorders than placebo (pooled OR 3.30; 95% CI 1.90–5.72; p < 0.001).[3]

Mechanism: Duloxetine's SUI effect is attributed to enhanced pudendal drive to the striated urethral sphincter during storage; noradrenergic activity may also contribute to SNRI-associated hesitancy or retention, particularly in patients with voiding dysfunction, BPH, or BOO.[4][5][44]

New hesitancy/retention: assess bladder emptying and other causes, review the suspected drug with its prescriber, and treat acute retention promptly. Dose adjustment or supervised withdrawal may be needed. Tamsulosin benefit is described mainly in cases/review literature; automatically adding it risks a prescribing cascade and orthostasis.[2][44]

The milnacipran label specifically warns that male patients with a history of obstructive uropathy may have higher GU AE rates.[43]

Sexual dysfunction​

All SNRIs carry FDA warnings about sexual dysfunction across sexes: ejaculatory delay or failure, decreased libido, and ED in men; decreased libido and delayed or absent orgasm in women. Inquire about sexual function before starting and periodically during treatment.[2][41][43]

For men with drug-associated delayed ejaculation, AUA/SMSNA advises substitution, dose adjustment or staged withdrawal of contributing medication . Changes are coordinated with the prescribing clinician. Evidence is insufficient to assess the risk-benefit ratio of oral pharmacotherapy for delayed ejaculation .[37]

A FAERS pharmacovigilance analysis found levomilnacipran had stronger reporting signals for some urinary/sexual events.[42]

SIADH / hyponatremia​

All SNRIs can cause SIADH-mediated hyponatremia, usually reversible on stopping; sodium below 110 mmol/L has been reported with duloxetine.[2] Older adults and patients on diuretics or volume-depleted are at greater risk; relevant for urologic patients on thiazides for stone prevention. Check sodium if confusion, falls or nausea develop.[2][45]

Prescribing boundaries and safety​

Use the licensed SUI regimen above where applicable. Male SUI is off-label.

  • Duloxetine safety: review BP, falls/orthostasis, urinary retention, liver disease/alcohol exposure, renal function, bleeding risk, sodium and serotonergic interactions. Serotonin syndrome can occur with triptans, tramadol, fentanyl, methadone, meperidine, linezolid, lithium, St John's wort and other serotonergic drugs, and rarely alone. SNRIs can increase bleeding, particularly with NSAIDs, aspirin or anticoagulants, so weigh this before surgery. Duloxetine also raises blood pressure (label: check BP before and during treatment) and carries a hepatotoxicity warning: stop if jaundice or clinically significant liver dysfunction develops. Avoid use with chronic liver disease/cirrhosis, substantial alcohol use or GFR below 30 mL/min under the US label.[2] Yentreve labeling contraindicates use in liver disease resulting in hepatic impairment or CrCl <30 mL/min, initiation in uncontrolled hypertension, and coadministration with CYP1A2 inhibitors such as ciprofloxacin or fluvoxamine. The US CYMBALTA label also advises avoiding potent CYP1A2 inhibitors; fluvoxamine increased duloxetine AUC about sixfold in a study of 14 men.[2][45]
  • MAOI switching: duloxetine requires at least 14 days after stopping an MAOI, and at least 5 days after stopping duloxetine before starting a psychiatric MAOI. If urgent linezolid or IV methylene blue is needed and alternatives are unsuitable, stop duloxetine before treatment, monitor for serotonin syndrome for five days or until 24 hours after the last interacting-drug dose (whichever comes first), and resume duloxetine no sooner than 24 hours after that last dose.[2]
  • Other SNRIs: venlafaxine can raise BP and requires renal adjustment. Milnacipran needs dose reduction for severe renal impairment and is not recommended in ESRD, rather than labeled as contraindicated for ESRD.[41][43]
  • Mood and withdrawal: monitor suicidality and activation; SNRI labels carry the antidepressant suicidality boxed warning. Taper instead of abrupt discontinuation, because discontinuation syndrome (dizziness, nausea, paresthesias, irritability, insomnia) can follow abrupt cessation or missed doses. Sexual adverse effects should be discussed before treatment and reassessed.[2][41][43]

Alpha-blockers and duloxetine act in opposing directions on outlet resistance; combining them may increase orthostatic symptoms. Avoid treating suspected drug-induced retention by reflexively adding another medicine.[2][44]

See Also​

References​

1. Wu JM. "Stress incontinence in women." N Engl J Med. 2021;384(25):2428–2436. doi:10.1056/NEJMcp1914037

2. Eli Lilly. CYMBALTA (duloxetine): prescribing information. Revised July 2025. DailyMed.

3. Trinchieri M, Perletti G, Magri V, et al. "Urinary side effects of psychotropic drugs: a systematic review and metanalysis." Neurourol Urodyn. 2021;40(6):1333–1348. doi:10.1002/nau.24695

4. Schuessler B. "What do we know about duloxetine's mode of action? Evidence from animals to humans." BJOG. 2006;113(Suppl 1):5–9. doi:10.1111/j.1471-0528.2006.00877.x

5. Thor KB. "Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence." Urology. 2003;62(4 Suppl 1):3–9. doi:10.1016/s0090-4295(03)00754-4

6. Thor KB, Katofiasc MA. "Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat." J Pharmacol Exp Ther. 1995;274(2):1014–1024. doi:10.1016/s0022-3565(25)10548-x

7. Miyazato M, Kitta T, Kaiho Y, et al. "Effects of duloxetine on urethral continence reflex and bladder activity in rats with cerebral infarction." J Urol. 2015;194(3):842–847. doi:10.1016/j.juro.2015.03.091

8. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

9. Redaelli M, Ricatti MJ, Simonetto M, et al. "Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice." PLoS One. 2015;10(3):e0121883. doi:10.1371/journal.pone.0121883

10. Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. "Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults." Cochrane Database Syst Rev. 2005;(3):CD004742. doi:10.1002/14651858.CD004742.pub2

11. Qaseem A, Dallas P, Forciea MA, et al. "Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians." Ann Intern Med. 2014;161(6):429–440. doi:10.7326/M13-2410

12. Hagovska M, Svihra J, Breza J, Dubravicky J, Vargovcak M. "A randomized, intervention parallel multicentre study to evaluate duloxetine and innovative pelvic floor muscle training in women with uncomplicated stress urinary incontinence — the DULOXING study." Int Urogynecol J. 2021;32(1):193–201. doi:10.1007/s00192-020-04516-w

13. Svihra J, Hagovska M, Breza J, et al. "Impact of innovative pelvic floor muscle training on quality-adjusted life years (QALYs) in women with stress urinary incontinence treated by duloxetine." Eur J Obstet Gynecol Reprod Biol. 2021;264:25–30. doi:10.1016/j.ejogrb.2021.06.025

14. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. "A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence." J Urol. 2005;173(5):1647–1653. doi:10.1097/01.ju.0000154167.90600.c6

15. Biyikoglu M, Kettas E, Sesli M, et al. "The effect of duloxetine on female sexual functions in the treatment of stress incontinence." Arch Gynecol Obstet. 2023;308(3):1037–1042. doi:10.1007/s00404-023-07123-4

16. Cornu JN, Merlet B, Ciofu C, et al. "Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial." Eur Urol. 2011;59(1):148–154. doi:10.1016/j.eururo.2010.10.031

17. Filocamo MT, Li Marzi V, Del Popolo G, et al. "Pharmacologic treatment in postprostatectomy stress urinary incontinence." Eur Urol. 2007;51(6):1559–1564. doi:10.1016/j.eururo.2006.08.005

18. Sanchez-Salas R, Tourinho-Barbosa R, Sivaraman A, et al. "Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: a randomized clinical trial." Prostate. 2024;84(2):158–165. doi:10.1002/pros.24634

19. Kang CS, Kim DH, Choi JH, et al. "Pelvic floor muscle exercise with or without duloxetine for postprostatectomy urinary incontinence: a retrospective single-center study." Medicine (Baltimore). 2023;102(32):e34657. doi:10.1097/MD.0000000000034657

20. Schlenker B, Gratzke C, Reich O, et al. "Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy." Eur Urol. 2006;49(6):1075–1078. doi:10.1016/j.eururo.2006.01.038

21. Collado Serra A, Rubio-Briones J, Puyol Payás M, et al. "Postprostatectomy established stress urinary incontinence treated with duloxetine." Urology. 2011;78(2):261–266. doi:10.1016/j.urology.2011.03.006

22. Castellan P, Ferretti S, Litterio G, Marchioni M, Schips L. "Management of urinary incontinence following radical prostatectomy: challenges and solutions." Ther Clin Risk Manag. 2023;19:43–56. doi:10.2147/TCRM.S283305

23. Sobay R, Küçük EV. "An investigation of the effect of combining tolterodine and duloxetine in the treatment of mixed-type urinary incontinence and the factors affecting success." J Clin Med. 2025;14(10):3575. doi:10.3390/jcm14103575

24. Polat H, Ekşi M, Çatık A, et al. "Clinical outcomes and safety of duloxetine and tolterodine combination in the treatment of mixed-type urinary incontinence: a single-arm retrospective study." J Int Med Res. 2026;54(3):3000605261430142. doi:10.1177/03000605261430142

25. Steers WD, Herschorn S, Kreder KJ, et al. "Duloxetine compared with placebo for treating women with symptoms of overactive bladder." BJU Int. 2007;100(2):337–345. doi:10.1111/j.1464-410X.2007.06980.x

26. Di Rezze S, Frasca V, Inghilleri M, et al. "Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study." Clin Neuropharmacol. 2012;35(5):231–234. doi:10.1097/WNF.0b013e3182613dce

27. Wróbel A, Serefko A, Woźniak A, et al. "Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways." Pharmacol Biochem Behav. 2020;189:172842. doi:10.1016/j.pbb.2019.172842

28. Giannantoni A, Porena M, Gubbiotti M, Maddonni S, Di Stasi SM. "The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome." Urology. 2014;83(2):400–405. doi:10.1016/j.urology.2013.09.024

29. Zhang M, Li H, Ji Z, Dong D, Yan S. "Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: an observational study." Medicine (Baltimore). 2017;96(10):e6243. doi:10.1097/MD.0000000000006243

30. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

31. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. "Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome." Drugs Aging. 2021;38(10):845–886. doi:10.1007/s40266-021-00890-2

32. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

33. Sunder M. "SSRIs and SNRIs for premature ejaculation in adult men." Am Fam Physician. 2022;105(6):591–592. PMID 35704830

34. Hoy SM, Scott LJ. "Dapoxetine: in premature ejaculation." Drugs. 2010;70(11):1433–1443. doi:10.2165/11204750-000000000-00000

35. Sathianathen NJ, Hwang EC, Mian R, et al. "Selective serotonin re-uptake inhibitors for premature ejaculation in adult men." Cochrane Database Syst Rev. 2021;3:CD012799. doi:10.1002/14651858.CD012799.pub2

36. Safarinejad MR. "Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study." Andrologia. 2008;40(1):49–55. doi:10.1111/j.1439-0272.2008.00813.x

37. Shindel AW, Althof SE, Carrier S, et al. "Disorders of ejaculation: an AUA/SMSNA guideline." J Urol. 2022;207(3):504–512. doi:10.1097/JU.0000000000002392

38. De Hong C, Ren LL, Yu H, Qiang W. "The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation." Sci Rep. 2014;4:7269. doi:10.1038/srep07269

39. Sridharan K, Sivaramakrishnan G, Sequeira RP, Al-Khaja KA. "Pharmacological interventions for premature ejaculation: a mixed-treatment comparison network meta-analysis of randomized clinical trials." Int J Impot Res. 2018;30(5):215–223. doi:10.1038/s41443-018-0030-x

40. Gul M, Bocu K, Serefoglu EC. "Current and emerging treatment options for premature ejaculation." Nat Rev Urol. 2022;19(11):659–680. doi:10.1038/s41585-022-00639-5

41. Pfizer. EFFEXOR XR (venlafaxine): prescribing information. DailyMed. Accessed September 12, 2026.

42. Huang T, Zhang P, Zhou Y, et al. "Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA Adverse Event Reporting System." Front Pharmacol. 2025;16:1719881. doi:10.3389/fphar.2025.1719881

43. SAVELLA (milnacipran): prescribing information. Revised September 2025. DailyMed.

44. Asnis GM, Caneva E, Henderson MA. "A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations." Expert Opin Drug Saf. 2016;15(5):717–725. doi:10.1517/14740338.2016.1164138

45. European Medicines Agency. Yentreve (duloxetine): product information. Current SmPC. Accessed September 12, 2026.

46. NICE. Urinary incontinence and pelvic organ prolapse in women (NG123). Recommendation 1.4.35. Guideline.

47. European Association of Urology. Non-neurogenic Female LUTS. 2026. Duloxetine section. Guideline.

48. European Association of Urology. Non-neurogenic Male LUTS. 2026. Drugs for stress urinary incontinence. Guideline.

49. Birkinshaw H, Friedrich CM, Cole P, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023;5:CD014682. doi:10.1002/14651858.CD014682.pub2.

50. Engeler D, Baranowski AP, Berghmans B, et al. EAU Guidelines on Chronic Pelvic Pain. European Association of Urology; limited update March 2026. Guideline

51. Allergan, Inc. FETZIMA (levomilnacipran): prescribing information. DailyMed. Updated April 30, 2024. Accessed October 3, 2026.

52. Allaire C, Yong PJ, Bajzak K, et al. "Guideline No. 445: Management of chronic pelvic pain." J Obstet Gynaecol Can. 2024;46(1):102283. doi:10.1016/j.jogc.2023.102283

53. Mohseni M, Ghaderzadeh R, Bakhtiari K, et al. "Tolerability and efficacy of duloxetine compared to amitriptyline in women with chronic pelvic pain syndrome: findings from a clinical trial." LUTS. 2025;17(4):e70023. doi:10.1111/luts.70023

54. Pfizer. DETROL (tolterodine): prescribing information. DailyMed.

55. Maund E, Guski LS, Gøtzsche PC. "Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports." CMAJ. 2017;189(5):E194–E203. doi:10.1503/cmaj.151104

56. Lai HH, Pontari MA, Argoff CE, et al. "Male chronic pelvic pain: AUA guideline: Part II treatment of chronic prostatitis/chronic pelvic pain syndrome." J Urol. 2025;214(2):127–137. doi:10.1097/JU.0000000000004565

57. European Association of Urology. EAU Guidelines on Sexual and Reproductive Health. 2026. Disorders of ejaculation. Guideline.

58. Zaazaa A, Nasr Eldin M, GamalEl Din SF, et al. "Daily intake of 30 mg duloxetine is effective in decreasing premature ejaculation severity: a prospective randomized placebo-controlled cross over clinical trial." Basic Clin Androl. 2023;33(1):34. doi:10.1186/s12610-023-00210-1

59. Kılıç S, Ergin H, Baydinç YC. "Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug." Int J Androl. 2005;28(1):47–52. doi:10.1111/j.1365-2605.2005.00507.x

60. Wyeth Pharmaceuticals LLC. PRISTIQ (desvenlafaxine): prescribing information. DailyMed, version 67 (April 2026). Label.